Table 2.
Summary of the studies included in the qualitative synthesis.
| Author (Published Year) [ref.] | Journal | Study Design | Time Spam | Pathogen | Septic Focus | Evaluation Time Points | ||
|---|---|---|---|---|---|---|---|---|
| Mortality | Clinical | Microbiological | ||||||
| Sousa (2018) [8] | J Antimicrob Chemother | RC | 04/16–12/17 | CRE (KPC: 95%) |
Mix | 30-days | 7-days | 7-days |
| King (2017) [26] | Antimicrob Agents Chemother | RC | 03/05–04/16 | CRE (KPC: 83%) |
Mix | In Hospital | end of therapy | end of therapy |
| Alraddadi (2019) [27] | BMC Infectious Diseases | RC | 01/17–08/18 | CRE (KPC: 79%) |
Mix | 30-days | 30-days | 30-days |
| Caston (2017) [6] | Int J Infect Dis | RC | 06/12–03/16 | CRE (KPC: 80%) |
Bacteremia | 30-days | 14-days | - |
| Shields (2017) [7] | Antimicrob Agents Chemother | RC | 01/09–02/17 | CRE (KPC: 100%) |
Bacteremia | 30-days | - | - |
| Tumbarello (2019) [5] | Clin Infect Dis | RC | 04/16–12/17 | CRE(KPC: 100%) | Bacteremia | 30-days | - | In Hospital* |
| Carmeli (2016) [19] | Lancet Infect Dis | RCT | 01/13–08/14 | MIX | cIAI / cUTI | 28-days | 7–10 days | 21/25-days |
| Lucasti (2013) [21] | J Antimicrob Chemother | RCT | 03/09–12/09 | MIX | cIAI | - | 14-days | 14-days |
| Qin (2017) [22] | Int J Antimicrob Agents | RCT | 01/13–03/15 | MIX | cIAI | - | 28–35 days | - |
| Mazuski (2016) [23] | Clin Infect Dis | RCT | 03/12–04/13 | MIX | cIAI | - | 28–35 days | 28–35 days |
| Vazquez (2012) [24] | Curr Med Res Opin | RCT | 11/08–06/10 | MIX | cUTI | - | 5–9 days | 5–9 days |
| Wagenlehner (2016) [25] | Clin Infect Dis | RCT | 10/10–08/14 | MIX | cUTI | - | 21–25 days | 21–25 days |
| Torres (2018) [20] | Lancet Infect Dis | RCT | 04/13–02/15 | MIX | NP | 21–25 days | 21–25 days | 21–25 days |
CRE: carbapenem-resistant Enterobacteriaceae; KPC: Klebsiella pneumoniae carbapenemasi; RC: Retrospective cohort study; RCT: Randomized controlled trial; Mix: Mixed bacterial flora; MIX: Aggregated foci of infection.